9-Jan-2026
Standard BioTools Exceeds 2025 Revenue Guidance, Projects $550M Cash Infusion from SomaLogic Sale
Market Chameleon (Thu, 8-Jan 6:52 AM ET)
TipRanks (Thu, 8-Jan 9:20 AM ET)
Seeking Alpha News (Thu, 8-Jan 7:40 AM ET)
Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue
Globe Newswire (Thu, 8-Jan 7:00 AM ET)
Business Wire (Wed, 19-Nov 11:30 AM ET)
PRNewswire (Mon, 10-Nov 12:15 PM ET)
Standard BioTools Reports Third Quarter 2025 Financial Results
Globe Newswire (Tue, 4-Nov 4:05 PM ET)
Standard BioTools to Announce Third Quarter Financial Results on November 4, 2025
Globe Newswire (Tue, 21-Oct 7:00 AM ET)
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
Standard Biotools trades on the NASDAQ stock market under the symbol LAB.
As of January 9, 2026, LAB stock price was flat at $1.54 with 2,060,531 million shares trading.
LAB has a beta of 1.41, meaning it tends to be more sensitive to market movements. LAB has a correlation of 0.15 to the broad based SPY ETF.
LAB has a market cap of $592.23 million. This is considered a Small Cap stock.
Last quarter Standard Biotools reported $20 million in Revenue and -$.09 earnings per share. This beat revenue expectation by $2 million and missed earnings estimates by -$.05.
In the last 3 years, LAB traded as high as $3.16 and as low as $.92.
The top ETF exchange traded funds that LAB belongs to (by Net Assets): VTI, IWM, VXF, ARKG, IBB.
LAB has underperformed the market in the last year with a return of -12.0%, while SPY returned +19.0%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in LAB shares. However, LAB has outperformed the market in the last 3 month and 2 week periods, returning +13.2% and +11.6%, while SPY returned +3.7% and +0.5%, respectively. This indicates LAB has been having a stronger performance recently.
LAB support price is $1.46 and resistance is $1.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LAB shares will trade within this expected range on the day.